Results 1 to 10 of about 18,115 (178)
Molecular Oncology, 2018 Although regorafenib has demonstrated survival benefits in patients with metastatic colorectal and gastrointestinal stromal tumors, no proven biomarker has been identified for predicting sensitivity to regorafenib.
Sae-Won Han
exaly +3 more sources
Cancer Medicine, 2023 Background Although the use of regorafenib plus nivolumab demonstrates promising outcomes in patients with refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC), this effect has not been substantiated in other studies.
Liangping Xia, Lei Wang, Gui-Fang Guo
exaly +2 more sources
Regorafenib Suppresses Migration of and Induces Cell Cycle Arrest and Apoptosis in MCF-7 Cells
Brazilian Journal of Pharmaceutical Sciences, 2021 This study investigated the mechanism underlying the suppression of estrogen receptor-positive MCF-7 cell growth by regorafenib. MCF-7 cells were treated with regorafenib, and the effect of regorafenib on multiple cancer-associated pathways was evaluated.
Dawei Wang, Ceji Fan, Jun Tang
doaj +2 more sources
Overcoming Regorafenib Resistance in Colorectal Cancer: Synergistic Efficacy of Cilengitide in HT29 and WiDr Cells [PDF]
Medeniyet Medical JournalObjective: Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide. Regorafenib, a multikinase inhibitor, is approved for the treatment of metastatic CRC; however, the emergence of drug resistance significantly limits ...
Asiye Busra BOZ +2 more
doaj +2 more sources
Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
Cancer Medicine, 2016 Regorafenib is an orally administered inhibitor of protein kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment.
Dieter Zopf +8 more
exaly +2 more sources
Cancer MedicineIntroduction Regorafenib remains the standard and widely used second‐line strategy for advanced hepatocellular carcinoma (HCC). There is still a lack of large‐scale multicenter real‐world evidence concerning the concurrent use of regorafenib with immune ...
Guo-Ying Wang, Yunfei Yuan
exaly +2 more sources
ERBB3 blockade sensitizes hepatocellular carcinoma to regorafenib after first-line tyrosine kinase inhibitor resistance by inhibiting HIF1A-ABCB1 signaling [PDF]
Clinical and Molecular HepatologyBackground/Aims Regorafenib is recommended by guidelines and trials as a sequential second-line therapy following progression on first-line sorafenib or lenvatinib in hepatocellular carcinoma (HCC).
Baorui Tao +8 more
doaj +2 more sources
Berberine Sensitizes Human Hepatoma Cells to Regorafenib via Modulating Expression of Circular RNAs
Frontiers in Pharmacology, 2021 Regorafenib resistance is a key limiting factor in the treatment of advanced hepatocellular carcinoma (HCC). Increasing evidence has demonstrated that Berberine (BBR) can synergistically enhance the therapeutic effect of various chemotherapeutic agents ...
Kunyuan Wang +8 more
doaj +1 more source
Frontiers in Cell and Developmental Biology, 2021 Hepatocellular carcinoma (HCC) is an aggressive, chemo resistant neoplasm with poor prognosis and limited treatment options. Exploring activated pathways upon drug treatment can be used to discover more effective anticancer agents to overcome therapy ...
Mustafa Karabicici +10 more
doaj +1 more source
Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma
Frontiers in Pharmacology, 2022 Background: The RESORCE trial reported that regorafenib was effective as the second-line treatment for patients with hepatocellular carcinoma (HCC) after progression on sorafenib.
Jing-Yu Hou +10 more
doaj +1 more source